Sanuwave Health, Inc. Delivers Record Q4 and Full Year 2025 Financial Results, Issues Robust Growth Guidance for 2026

Key Highlights

• Q4 2025 Revenue: \$13.4 million, up 29.7% year-over-year, an all-time quarterly record for the company.
• Full Year 2025 Revenue: \$44.1 million, up 35% from 2024, marking a new annual record.
• Q4 UltraMIST® System Sales: 255 units sold, up from 135 units in Q4 2024 and 155 units in Q3 2025.
• UltraMIST® Consumables Revenue: \$6.5 million in Q4 2025, up 10.6% year-over-year (48.7% of total Q4 revenue).
• Gross Margin: Q4 at 74.7% (would have been 78.3% excluding a \$486K inventory write-off). Full year gross margin was 77.1% vs 75.2% in 2024.
• Q4 Operating Income: \$2.0 million (impacted by inventory write-off and \$479K sales tax expense; would have been \$3.0 million otherwise).
• Q4 Net Income: \$7.7 million, a dramatic turnaround from a net loss of \$13.3 million in Q4 2024.
• Adjusted EBITDA (Q4): \$4.8 million, up from \$3.7 million in Q4 2024.
• Full Year 2025 Adjusted EBITDA: \$13.6 million, up from \$7.2 million in 2024.
• 2026 Guidance: Q1 revenue expected between \$9.6-10.3 million (up 3-10% year-over-year), and full-year revenue guidance of \$51–55 million (16-25% growth).

In-Depth Financial & Operational Review

Strong Growth in Core UltraMIST® Business

Sanuwave Health, Inc. continues to see robust demand for its flagship UltraMIST® systems and consumables, which are now the primary revenue drivers and represented nearly all of the company’s revenues for Q4 and the full year. The company sold 624 UltraMIST® systems in 2025, up from 374 in 2024, and consumables revenue for the full year surged by 27.4% to \$25.5 million (58% of 2025 revenue).

The increase in UltraMIST® system adoption and recurring consumables sales demonstrates broad acceptance of the technology in the wound care market, despite industry headwinds.

Margin and Profitability Developments

Gross margin for Q4 dipped to 74.7% from 77.9% in Q4 2024, impacted by a one-time \$486,000 write-off of PACE inventory as that product line was sunsetted. Excluding this charge, gross margin would have improved to 78.3%. Full year 2025 gross margin improved to 77.1% from 75.2% in 2024, reflecting operational efficiencies and a favorable product mix.

Operating income for Q4 was \$2.0 million, flat year-over-year, but would have reached \$3.0 million without the aforementioned one-time charges. Full-year operating income rose to \$4.9 million, up \$1.1 million from 2024, reflecting continued efforts to drive profitable growth and expense management.

The company reported a net income of \$11.8 million for 2025, a significant turnaround from a net loss of \$33.1 million in 2024. The swing was primarily due to changes in the fair value of derivative liabilities, as well as improved operating profit and other income factors.

Adjusted EBITDA for the year was \$13.6 million, marking a \$6.5 million improvement over 2024 and confirming the company’s enhanced profitability and cash generation.

Balance Sheet and Cash Flow Improvements

Sanuwave ended 2025 with \$11.96 million in cash and cash equivalents, up from \$10.24 million at the end of 2024. The company generated cash from operations of \$3.88 million for the year, compared to \$2.46 million in 2024. It also recorded proceeds from the sale of patents and managed debt efficiently, repaying and restructuring several credit facilities.

The company’s total assets increased to \$37.3 million, and stockholders’ equity turned positive to \$1.6 million from a deficit of \$(15.8) million in 2024, reflecting its improved financial position.

Market Dynamics and Strategic Positioning

CEO Morgan Frank highlighted the turbulent environment in wound care, citing significant CMS reimbursement cuts to skin substitutes and an intensified audit climate. These factors have led to the exit or downsizing of many mobile wound care providers, but simultaneously opened new opportunities for Sanuwave. The company has capitalized by partnering with a greater number of skilled distributors and resellers—many of whom are shifting away from skin substitutes to promote UltraMIST®. This increased “feet on the street” is expected to drive future growth.

While some sales were offset by customers exiting the market or reducing volumes, the company expects that CMS’s focus on value and medical necessity will ultimately benefit UltraMIST®, which is well positioned as a cost-effective and clinically valuable solution.

Important Notes & Shareholder Considerations

• One-Time Charges: Q4 results were affected by a \$486K inventory write-off and a \$479K sales tax expense. These are non-recurring and, when adjusted, show even stronger underlying profitability.
• Major Profit Turnaround: The swing from a \$33M net loss to nearly \$12M net income in one year is material and likely to influence investor sentiment and share price direction.
• Guidance for 2026: Management is confident in ongoing growth, forecasting 16-25% revenue growth for 2026. Meeting or exceeding this guidance could be a catalyst for share price appreciation.
• Improved Capital Structure: The company moved from a significant equity deficit to positive equity, reducing financial risk and improving the outlook for potential future financings or strategic initiatives.
• Industry Changes: The CMS-driven shifts in the wound care market may create both risk and opportunity. Sanuwave’s ability to capture share from exiting competitors and leverage new distributor relationships is a key story for investors to watch.
• Conference Call: Investors should note the upcoming business update conference call on March 27, 2026, which may provide additional insights into strategy and outlook.

Conclusion

Sanuwave Health, Inc. has delivered record financial results for both Q4 and the full year 2025, with growth driven by strong UltraMIST® system adoption and consumables sales. The company has not only returned to profitability but is also guiding for significant growth in 2026, even as the wound care industry undergoes rapid change. Investors should watch for further updates and monitor the company’s ability to execute in this dynamic environment.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with a financial advisor before making investment decisions. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected.

View SANUWAVE Health, Inc. Historical chart here